Kevin Kraus has over 25 years of commercial leadership in diagnostics, pharmaceuticals, and precision medicine. At Genentech, Roche, and Ventana Medical Systems (acquired by Roche), he led global product launches, shaped biomarker access strategies, and scaled oncology and pathology innovations.
As Vice President of Marketing and Pricing Analytics at Roche, he oversaw the global Tissue Diagnostics portfolio, launching instruments, companion diagnostics, and digital pathology platforms. While based in Switzerland, he managed a large global immunoassay portfolio and partnered with Roche Pharma oncology teams to advance biomarker-driven care for new therapeutics.
Kevin now advises early-stage biotech companies on diagnostic commercialization, investor due diligence, and pharma partnerships, including work with a Third Rock Ventures-backed startup. His experience translating emerging diagnostic technologies into clinical and commercial value aligns closely with FYR’s mission. He holds a BA from George Washington University and an MBA from the University of Arizona.